As of June 10, 2025, CStone Pharmaceuticals (2616.HK) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing CStone Pharmaceuticals's Forward P/E to Peers
To better understand CStone Pharmaceuticals's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| CStone Pharmaceuticals (2616.HK) | - |
| HOB Biotech Group Corp Ltd (688656.SS) | 129.62 |
| Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336.SS) | 124.09 |
| BrightGene Bio-Medical Technology Co Ltd (688166.SS) | 90.45 |
| Beijing Balance Medical Technology Co Ltd (688198.SS) | 75.87 |
| Guanhao Biotech Co Ltd (300238.SZ) | 72.32 |
Compared to its competitors, CStone Pharmaceuticals's Forward P/E is difficult to compare due to insufficient data.